SloveniaSlovenia

Lek Defends Patent for Omeprazole

05.02.2004

Ljubljana - Slovenian pharmaceutical company Lek d.d. successfully defended in late December its patent EP 1 095 037, which covers Lek's synthesis of Ome-prazole before the Board of Appeal of the European Patent Office.
Omeprazole is the world's second largest selling pharmaceutical product used for treating stomach ailments, especially duodenal and stomach ulcers. Lek, having developed its own patent-free formulation, markets Omeprazole in Slovenia and in its traditional markets of Central, Eastern and South-Eastern Europe, and since the beginning of August 2003 also in the world's most demanding pharmaceutical market, the US market. Lek has already received five patents for this process, including US and European patents.
The originator AstraZeneca filed an appeal against the granting of a European patent alleging that the Lek patent was not new and inventive with respect to the known literature at the time of the filing of the first application. AstraZeneca owns several patents for this drug. They refer to the manufacturing process, use and pharmaceutical form of the drug. AstraZeneca markets its product under the registered trademark Prilosec/Losec. US sales of Prilosec in 2002 reached around $4 billion. AstraZeneca's basic patent for Omeprazole expired in October 2001, but there are other patents which expire progressively up to 2014. The first generic manufacturer, the company KUDCo/Schwarz Pharma, launched its generic Omeprazole in the US in December 2002.
Lek will market Omeprazole in the European Union within the framework of Sandoz, the generics section of Novartis. Lek creates value through the use of its own produced active pharmaceutical ingredient and its own pharmaceutical form in the final product.

SloveniaSlovenia

05.03.2010

Ljubljana – Slovenian drugmaker Krka d.d. turned in a solid performance in 2009, with total sales reaching EUR950m, similar to turnover in 2008. Profits rose by around 10% year-on-year to EUR173.7m. The results announced at the...

SloveniaSlovenia

27.08.2009

Ljubljana – Pharma giants Warner-Lambert and Pfizer have withdrawn their lawsuit against the Slovenian generic manufacturer Krka d.d over the infringement of two patents concerning their US$12bn blockbuster drug Lipitor...

SloveniaSlovenia

29.04.2009

Ljubljana – BIA Separations d.o.o., the Slovenian specialist for downstream processing of biologicals using monoliths, has received an EUR8m cash injection from the European Investment Bank (EIB). EIB president Philippe Maystadt...

SloveniaSlovenia

21.02.2009

Ljubljana – The most talented young synthetic biologists currently seem to be coming from Eastern Europe. After its success in 2006, a team of young undergraduate chemists from the University of Ljubljana has once again won the...

SloveniaSlovenia

01.11.2008

Belgrade/Lund – Swedish developer of probiotic bacteria Probi AB (Lund) has signed a distribution agreement with Serbian pharmaceutical company Proton System (Belgrade). The agreement gives Proton System the right to sell one of...

SloveniaSlovenia

14.02.2008

Ljubljana/Brussels – Slovenia, which took over the EU presidency from Portugal in January, will put its health-care focus on improving the management of cancer, representatives announced on the presidency website...

Germany, SloveniaSlovenia

24.10.2007

Zagreb – Barr-PLIVA d.d.’s German subsidiary AWD.pharma GmbH & Co. KG. has signed an agreement to acquire O.R.C.A.pharm GmbH (“ORCApharm“), a privately owned specialty pharmaceutical company focused on the oncology market in...

SloveniaSlovenia

17.05.2007

Ljubljana – Slovenia’s national prevention scheme has led to a very low rate of new HIV infections. According to Slovenias’ health minister, Andrej Brucan, fewer than one in 1000 people is infected with the AIDS virus.

SloveniaSlovenia

21.11.2006

Zagreb – Consolidation of the generic-drug business is focusing on eastern Europe. So far in 2006, at least eight deals have been announced, including Barr Pharmaceuticals‘ US$2.5-billion acquisition of Croatia‘s Pliva, completed...

SloveniaSlovenia

21.07.2006

Zagreb – In the bidding race between the Icelandic Actavis Group and US Barr Pharmaceuticals Inc. for the takeover of the Croatian biogenerics producer Pliva d.d., the company ultimately opted for Barr’s offer. Both companies’...

Displaying results 1 to 10 out of 22

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-slovenia/article/lek-defends-patent-for-omeprazole.html

Product of the week

Products

Events

All Events

Current issue

All issues